Literature DB >> 18468534

The COOPERATE trial: a letter of concern.

Regina Kunz, Marcel Wolbers, Tracy Glass, Johannes F E Mann.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18468534     DOI： 10.1016/S0140-6736(08)60681-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  16 in total

Review 1.  Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.

Authors:  Raimund H Pichler; Ian H de Boer
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

2.  Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue?

Authors:  G D Laverman; S J L Bakker; G J Navis
Journal:  Diabetologia       Date:  2009-03-18       Impact factor: 10.122

Review 3.  Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.

Authors:  M Dalla Vestra; N Simioni; A Masiero
Journal:  Int Urol Nephrol       Date:  2008-10-29       Impact factor: 2.370

Review 4.  Renal failure (chronic).

Authors:  Catherine Clase
Journal:  BMJ Clin Evid       Date:  2011-05-25

5.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

Review 6.  Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?

Authors:  Kunal Chaudhary; Ravi Nistala; Adam Whaley-Connell
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

Review 7.  Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy.

Authors:  Sheldon W Tobe; Monica O Dai
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

Review 8.  [Kidney and hypertension].

Authors:  I Quack; L C Rump
Journal:  Internist (Berl)       Date:  2009-04       Impact factor: 0.743

9.  Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Authors:  Linda F Fried; William Duckworth; Jane Hongyuan Zhang; Theresa O'Connor; Mary Brophy; Nicholas Emanuele; Grant D Huang; Peter A McCullough; Paul M Palevsky; Stephen Seliger; Stuart R Warren; Peter Peduzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 8.237

Review 10.  Results of the ONTARGET and TRANSCEND studies: an update and discussion.

Authors:  David Fitchett
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.